from Reuters: Top News https://ift.tt/2FDJnsa Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.
U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million
Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.
from Reuters: Top News https://ift.tt/2FDJnsa Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.
from Reuters: Top News https://ift.tt/2FDJnsa Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.
Related Posts:
Australia investigates reports Chinese-Australian writer is missing in China- Cardiff City's Sala missing after plane disappears over English Channel
- Pakistani police to face murder charges over killing of family
- Soccer: Ranieri devastated by Sala's disappearance
- Venezuela's opposition takes to streets to seize momentum against Maduro
0 comments:
Post a Comment